Intravitreal Nesvacumab (Anti-Angiopoietin 2) Plus Aflibercept in Diabetic Macular Edema: The Phase 2 RUBY Randomized Trial.
Sign Up to like & getrecommendations! Published in 2022 at "Retina"
DOI: 10.1097/iae.0000000000003441
Abstract: PURPOSE To compare intravitreal nesvacumab (anti-angiopoietin 2) plus aflibercept with intravitreal aflibercept injection (IAI) in diabetic macular edema (DME). METHODS Eyes (n=302) were randomized (1:2:3) to nesvacumab 3 mg+aflibercept 2 mg (LD combo), nesvacumab 6… read more here.
Keywords: nesvacumab anti; plus aflibercept; angiopoietin plus; week ... See more keywords